Melanotan I

What it is

Melanotan I tells your skin to make more of its own pigment, so a little sun gives you a tan that used to take weeks of burning. It is the selective, better-tolerated melanotan: no libido spike, less nausea, a slower and more natural color than Melanotan II. The version called afamelanotide is an approved medicine for a rare light-sensitivity disease, so this one has human trials behind it. The thing to respect is that it darkens every pigment cell you have, moles included.

The typical user is fair-skinned, burns before they tan, and is tired of it: redheads and pale blondes, people who want a base before a beach holiday or a wedding, and people with sun-sensitive skin who have noticed they tolerate more light with a tan. Melanotan I is what people who tried Melanotan II and hated the nausea or the erections move to. It is also what people with a family tan but an office job use to look like they have been outside.

The timeline: with a daily loading dose and a little sun or a short tanning-bed session every couple of days, color starts in the first week and is obvious by two to three weeks. Without any UV, not much happens; the peptide loads the pigment machinery, light develops it. Freckles and moles darken first, which surprises people. Once you have the color you want, two or three doses a week hold it, and it fades over a month or two when you stop. It will not protect you from burning the way sunscreen does, even though you will burn less.

Start at 0.5 mg subQ daily, which is 5 units of a 10 mg vial mixed with 1 ml. Hold there a week to see how your stomach handles it, then go to 1 mg if you want faster color; most people never need the 2 mg 'aggressive' tier or the 3 mg two or three times a week pattern, which is where the nausea lives. A 10 mg vial is 20 days at 0.5 mg, so one vial covers a loading phase. The mistakes: starting at the top tier and spending the first evening nauseous, dosing with no UV and concluding it is fake, doubling the sun exposure because you 'cannot burn now', and running Melanotan II alongside because a friend said it works faster.

Evidence sits at animal 3, human 3. Afamelanotide, the same peptide as a slow-release implant, went through Phase 3 trials and is approved in the US and Europe for erythropoietic protoporphyria, a disease where sunlight causes pain, and it has been studied for vitiligo and polymorphic light eruption. That is a real human safety record at medical doses. What has not been studied is cosmetic use of gray-market vials over years, and the open question nobody has answered is whether darkening and multiplying pigment cells changes melanoma risk; the data so far says moles darken and new ones appear, not that cancers do, and that is a gap rather than reassurance.

Not for you if you have had melanoma, have a lot of atypical moles, or have a first-degree relative with melanoma; the mole-watching burden is not worth a tan. Not worth it if you want libido or appetite effects; that is Melanotan II, with its own costs. If skin texture or glow rather than color is the goal, GHK-Cu or the GLOW blend is the better buy. Get a baseline skin check and photograph your moles before the first dose, because a dermatologist will want to know what changed.

What people use it for

How it works

Where Melanotan I sits among the melanocortins

Safety, in brief

The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.

Sources

The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.

1. Scenesse (afamelanotide) prescribing informationDailyMed: Scenesse (afamelanotide) · Label
2. Afamelanotide for Erythropoietic ProtoporphyriaLangendonk et al., N Engl J Med 2015 · Trial
3. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropinLevine et al., JAMA 1991 · Trial
4. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humansDorr et al., Photochem Photobiol 2000 · Trial